The following is a summary of the Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript:
Financial Performance:
Kamada Ltd. reported a Q2 2024 revenue of $42.5 million, a 13% increase from Q2 2023.
Adjusted EBITDA for Q2 2024 was $9.1 million, a 51% increase compared to Q2 2023.
First half 2024 revenues reached $80.2 million, an 18% increase year-over-year, and adjusted EBITDA was $16.6 million, a 68% increase.
Gross profit for Q2 2024 was $19 million with a margin of 45%, compared to $14.4 million or 39% margin year-over-year.
Net income for Q2 2024 was $4.4 million, compared to $1.8 million in Q2 2023.
Business Progress:
Launched first biosimilar product in Israel, planning another by year-end.
Expanding U.S. plasma collection operations with new centers in Beaumont, Houston, and San Antonio.
Ongoing pivotal Phase 3 clinical trial of inhaled AAT product.
Opportunities:
Anticipate increasing importance of biosimilars in distribution with potential annual sales between $30 million to $34 million.
Each new plasma collection center contributes $8 million to $10 million annual revenue.
Aiming for double-digit growth beyond 2024 supported by business development and M&A opportunities.
Risks:
Biosimilar product launches and clinical trials involve inherent risks, including regulatory and market acceptance challenges.
Plasma collection expansion and successful execution of M&A transactions are critical for sustained growth.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.